<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01547078</url>
  </required_header>
  <id_info>
    <org_study_id>2011-I-LyP-2</org_study_id>
    <nct_id>NCT01547078</nct_id>
  </id_info>
  <brief_title>Clinical Study of Lyophilized Plasma in Patients With Liver Disease</brief_title>
  <official_title>A Phase 2 Clinical Study of Lyophilized Plasma in Patients With Acquired Coagulopathy Due to Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HemCon Medical Technologies, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HemCon Medical Technologies, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, phase 2, randomized, controlled study of the effect of lyophilized plasma in
      patients with liver disease.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess and compare adverse events</measure>
    <time_frame>Duration of Study (Less than or equal to 7 days)</time_frame>
    <description>The primary safety objective is to assess the incidence of adverse events of lyophilized plasma compared to control.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Liver Disease</condition>
  <arm_group>
    <arm_group_label>Licensed Plasma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lyophilized Plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lyophilized Plasma</intervention_name>
    <description>Licensed plasma that has been lyophilized.</description>
    <arm_group_label>Lyophilized Plasma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Licensed Plasma</intervention_name>
    <description>Plasma that has been authorized for transfusion.</description>
    <arm_group_label>Licensed Plasma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients at least 18 years of age.

          2. Patients with liver disease.

          3. Patients who have need for plasma therapy for a surgical or an invasive procedure or
             who have evidence of bleeding.

          4. Patients with an elevated international normalized ratio due to liver disease.

          5. Patients who have given written informed consent or for whom written informed consent
             has been obtained from the patient's legal representative on their behalf.

          6. Patients able and willing to comply with the procedures laid out in the study
             protocol.

        Exclusion Criteria:

          1. Patients who are clinically unstable.

          2. Patients who have received mediations that could interfere with results of laboratory
             testing.

          3. Patients who have congenital or acquired coagulopathies of non-hepatic origin.

          4. Pregnant or nursing women.

          5. Active illicit drug use.

          6. Patients participating in another clinical treatment study currently or during the
             past 1 month prior to study inclusion.

          7. Patients previously enrolled in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2012</study_first_submitted>
  <study_first_submitted_qc>March 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2012</study_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

